Single-pill combination of empagliflozin, linagliptin and metformin for blood sugar control
Official title: Glycemic Control With Triple Pathway Approach Through Empagliflozin-Linagliptin-Metformin
Run by Nabiqasim Industries (Pvt) Ltd · NCT06862739 · Data updated 2026-11-12
This test tries a single pill that combines empagliflozin, linagliptin, and metformin to lower blood sugar and simplify treatment for adults with type 2 diabetes who have HbA1c of 8% or higher and are already on two or more diabetes medicines.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 800 (estimated) |
| Sponsor | Nabiqasim Industries (Pvt) Ltd Industry-sponsored |
| Locations | 2 sites (Faisalabad, Punjab Province and 1 other locations) |
| Status | Recruiting |
| Started | October 30, 2025 |
| Main results expected | April 30, 2026 |
| Study ends | June 30, 2026 |
| Registry record updated | April 17, 2026 |
| Trial ID | NCT06862739 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–80 with type 2 diabetes for at least six months, HbA1c of 8% or higher, already taking two or more anti-diabetic drugs, without allergy to empagliflozin, linagliptin, or metformin, and with adequate kidney function are ideal candidates.
✕Probably not a fit
Patients with type 1 diabetes, diabetes duration under six months, eGFR below 30 mL/min, pregnant or lactating women, those on GLP-1/GIP therapies, or with end-stage heart failure are unlikely to benefit or are excluded.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 4 interventional study gives adults with longstanding type 2 diabetes a fixed-dose single pill containing empagliflozin, linagliptin, and metformin and follows clinical outcomes at outpatient clinics in Punjab, Pakistan. Key outcomes include change in HbA1c, treatment adherence, weight, frequency of hypoglycemic events, quality of life, and treatment satisfaction. Eligible participants are adults aged 18–80 with T2DM for at least six months, HbA1c ≥8%, and already taking two or more oral anti-diabetic agents; major exclusions include severe renal impairment, type 1 diabetes, pregnancy, and recent use of GLP-1/GIP therapies. The study aims to test whether combining three oral agents into one fixed-dose pill can reduce pill burden and improve real-world metabolic control and patient-reported outcomes.
Why it matters
Potential benefit: If successful, the triple-pill could simplify medication regimens, improve adherence, and lead to better blood sugar control with potential benefits for weight and fewer hypoglycemic episodes.
How similar studies have gone: Prior studies combining SGLT2 inhibitors, DPP-4 inhibitors, and metformin have shown improved glycemic control and acceptable safety, though fixed-dose triple-pill formulations have been less extensively studied.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria 1. Patients of any gender 2. Patients aged between 18-80 years 3. Patients having HbA1c 8 % or above 4. Patients diagnosed with type II diabetes (more than at least 06 months) 5. Patients already on at least 02 or more anti-diabetic agents 6. Patients not allergic to empagliflozin, linagliptin, or metformin Exclusion criteria 1. Patients with age less than 18 2. Patients with Type-I diabetes 3. Patients having diabetes for less than 06 months 4. Patients on GLP-1 and GIP 5. Patients who are pregnant or lactating females 6. Patients with decompensated chronic liver disease (DCLD) 7. Patients with eGFR less than 30 ml 8. Patients with end-stage heart failure (NYHA Class 4) 9. Patients who are allergic to empagliflozin, linagliptin, or metformin 10. Patients who are not willing to consent 11. Patients who are unable to give medical history
Where it's running
-
Faisalabad clinics
Faisalabad, Punjab Province, Pakistan Recruiting -
Aap ka Clinic
Lahore, Punjab Province, Pakistan Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Preventing lower limb artery disease in adults with diabetes using a risk-prediction model and HAPA-based nursing
A risk-prediction model is tested in adults with type 2 diabetes to see if a nursing plan based on the HAPA model can reduce peripheral artery disease in the legs.
-
DiaFootCare: a mobile app to help adults with diabetic foot ulcers manage self-care in Oman
A mobile app called DiaFootCare will be tested to see if it helps adults with diabetic foot ulcers in Oman take better care of themselves and improve healing compared with usual care.
-
Predictive CGM with App for people with type 1 or insulin-treated type 2 diabetes
This study tests whether using the Accu-Chek SmartGuide CGM with its Predict App can reduce fear of hypoglycemia and improve related behaviors and confidence in adults with type 1 or insulin-treated type 2 diabetes.
-
SugarVita 2.0: a 12-week digital game for adults with type 2 diabetes
This 12-week pilot tests SugarVita 2.0, a serious digital game, to see if it helps adults with type 2 diabetes manage their condition and feel more confident.
-
Linking social care with healthcare to help manage chronic diseases
This trial tests whether pairing patients with trained community health workers can help them get transportation, healthy food, information, and better access to care to improve health in conditions like hypertension, diabetes, and high cholesterol.
-
Transcutaneous and topical photobiomodulation for diabetic foot ulcers
This phase 2 trial tests whether combining transcutaneous and topical photobiomodulation helps heal foot ulcers in adults with diabetes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.